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Abstract
Background: Vascular complications, such as HAT, are an important cause of graft loss and recipient mortality. We
aimed to characterize post-transplant thrombotic events in a cohort of liver transplant recipients, and identify
independent risk factors for these complications.
Methods: We conducted a thrombophilic study of 293 orthotopic liver transplants performed in the Digestive
Surgery Department of the 12 de Octubre Hospital (Madrid, Spain) between January 2001 and December 2006.
Results: The most frequent post-transplant thrombotic events were HAT (9%) and PVT (1.7%). The one variable
associated with post-transplant thrombotic event was a high fibrinogen level in the global cohort of liver
transplantation. But toxicity as event post-OLT has been associated with post-transplant thrombotic event in the
retrospective group and high fibrinogen level and low protein C levels were associated post-transplant thrombotic
event in the prospective group. Liver disease relapse (HR 6.609, p < 0.001), high levels of FVIII (HR 1.008, p = 0.019))
and low levels of antithrombin (HR 0.946, p < 0.001) were associated with poor overall survival (OS).
In conclusion, high fibrinogen and decreased protein C levels were associated with allograft thrombosis. Further
studies are required in order to assess the clinical relevance of these parameters in prospective studies and to
study the effect of anticoagulation prophylaxis in this group of risk.
Background
Vascular complications after orthotopic liver transplan-
tation (OLT) are one of the most feared problems that
frequently result in graft and patient loss. Early hepatic
artery thrombosis (eHAT) is a major complication fol-
lowing liver transplantation and since Starzl’s first report
on human liver transplantation it is recognized as an
important cause of graft loss and mortality [1,2].
HAT is generally believed to result primarily from sur-
gical techniques (kinking, stenotic anastomosis). How-
ever, some studies show that eHAT is also associated
with no-surgical factors, such as donor age [3], rejection,
and sluggish flow through the hepatic artery [1,4,5]. The
presence of Factor V Leiden in the graft [6,7], or
changes in the hemostatic system [8-11], are also
believed to play a role.
Recently a meta-analysis of the incidence, risk factors
and outcome of eHAT after liver transplantation showed
the risk factors of eHAT to be cytomegalovirus (CMV)
mis-match, re-transplantation, arterial conduits, pro-
longed operation time, low recipient weight, variant
arterial anatomy, and low volume transplant centers
[12]. However, the determinants of thrombophilia were
not included in this study.
We aimed to characterize post-transplant thrombotic
events in a cohort of liver transplant recipients, and to
identify possible parameters that could lead to HAT and
could be responsible for graft loss due to thrombosis in
extended thrombophilia study.
* Correspondence: rayaladiaz@hematologia12octubre.com
1Hematology Department, 12 De Octubre University Hospital, Madrid, Spain
Full list of author information is available at the end of the article
Ayala et al. BMC Gastroenterology 2011, 11:130
http://www.biomedcentral.com/1471-230X/11/130
© 2011 Ayala et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Methods
Patient population
Between January 2001 and December 2006, 441 orthoto-
pic liver transplants (OLT) were performed in the
D i g e s t i v eS u r g e r yD e p a r t m e n to ft h e1 2d eO c t u b r e
Hospital (Madrid, Spain). There were 441 grafts and 437
liver recipients. Before initiating this study, 74 recipients
had died (14 of whom demonstrated a thrombo-embolic
event [TE], and in two of these this was considered to
be the cause of death). In another 74 cases, we were
unable to obtain laboratory results because the referred
patients did not attend follow-up visits at our study cen-
ter, or did not sign the consent form. Wherever possible
all patients are lab tested for hypercoagulation study
irrespective of any presence of thrombophilia.
We have therefore reported analytical thrombophilia
results for 293 patients. As this study was initiated in July
2004, the majority of patients had already undergone
OLT. Thus, blood samples for these patients could only
be taken at their post-transplant follow-up visits. The
present work is made up of a retrospective study that
includes 167 patients up to July 2004 and a later prospec-
tive study that includes another 126 patients. Blood sam-
ples were taken at a median of 26.3 months and 3.1
months post-transplantation in the retrospective and
prospective studies, respectively. Patients of the retro-
spective group were evaluated by medical reports. From
2004, the evaluation was prospective for all patients,
monthly of quarterly. Clinical and analytical studies were
utilized for evaluation of patients. Abdominal Doppler,
computed tomography scan, or hepatic biopsies were car-
ried out whenever necessary. The analysis has been done
separately in both the prospective and retrospective
groups. The study was approved by our Ethical Institu-
tional Review Board and all patients gave their consent
for blood samples to be further processed. Data on
thrombophilia risk factors were collected by personal
interview, or by reviewing the medical history.
Recipients
The study population comprised 293 males and 144
females ranging from 1 month to 74.5 years old (median
51.73 y). Two-hundred and eighty-six cases were pri-
mary OLTs, 46 were secondary OLTs, and 9 cases were
tertiary OLTs. The cause of liver transplantation was: 20
HBV (hepatitis B virus), 57 HCV (hepatitis C virus), 40
HBV and HCV, 53 Ethanol, 8 Autoimmune, 7 Toxicity,
68 Tumor, 16 Alpha 1 antitrypsin deficits, 14 Biliary
atresia. We use “toxicity” to mean liver damage probably
caused by immunosuppressant therapy diagnosed by
liver biopsy. Three patients have received anticoagula-
tion therapy pre-OLT and 11 patients anticoagulation
therapy post-OLT. These patients were considered
separately. Post-OLT immunosuppressant regimen was
triple therapy: FQ (tacrolimus) or CsA (cyclosporine),
MMF (mycophenolate mofetil) and Cc (corticosteroids).
Corticosteroid is administred for 1 month post-OLT
(1mg/kg/day), and is later reduced to zero.
Donors
Forty-one live donor liver transplantation (LDLT), and
252 deceased donor liver transplantation (DDLT) donors
were evaluated. Eighty-six partial graft livers were
employed in the cases of DDLT. LDLT donors com-
prised 24 males and 17 females with a median age of 32
y (range, 19-52 y). LDLT donors were assessed before
OLT using functional coagulation and genetic tests. In
DDLT donors, only genetic tests were carried out.
Genetic studies were performed in 293 recipients and
222 donors (181 deceased, and 41 living donors).
Seventy one donor samples were not suitable.
Methods
Genetic thrombophilia study
The extracted genomic DNA was processed to detect
Factor V Leiden, prothrombin G20210A and methylene-
tetrahydrofolate (MTHFR) C667T mutations, using real-
time PCR (polymerase chain reaction) with hybridization
probes in a light-cycler (Roche Diagnostics, Mannheim,
Germany). We have tested these genetic mutations in a
subgroup of donors and recipients appropriately
matched and the tests were performed in the donors on
blood samples collected at the time of procurement.
Functional coagulation and hemostatic tests
The following panel of tests was run: prothrombin activity
(PA) (Dade Behring, Marburg, Germany) (This test is the
prothrombin time expressed as a percent and for their
interpretation, the normal range is 75-130% and a low per-
cent indicates a prolonged prothrombin time), activated
partial thromboplastin time (APTT) (Biomérieux, Cra-
ponne, France), and thrombin clotting time (TT) (Biomér-
ieux, Craponne, France). Fibrinogen concentration was
measured with a coagulometric assay using the Clauss
method (Biomérieux, Craponne, France). AT (Chromo-
genix, Mölndal, Sweden), PC (Roche Diagnostics, Man-
nheim, Germany), and PS (Roche Diagnostics, Mannheim,
Germany) activities were measured using chromogenic
substrate assays. PS antigen levels were assessed by
enzyme linked immunosorbent assay (ELISA) (Diagnostic
Grifols, Barcelona, Spain). Levels of homocysteine were
measured by fluorescent polarization immunoassay (FPIA)
using the Abbott Laboratories IMX System (Abbott park,
Illinois, USA). Hyperhomocysteinemia was defined as a
homocysteine level > 14 μmol/L. Activated PC resistance
(APCR) was measured by Coatest APC resistance
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cardiolipin antibodies were measured using the APhL
®
ELISA Kit (Grifols Engineering, Barcelona, Spain). Platelet
counts were done on the ADVIA 2120 (Siemens AG,
Munich, Germany). Factor VIII was measured by one-
stage clotting assays (Dade Behring, Marburg, Germany)
and was said to be increased at levels above 150 IU/dL.
Follow-up
Data on the clinical evolution of recipients were collected
by searching their medical records. Deep vein thrombosis
( D V T ) ,o r g a nv e i nt h r o m b o s i s( P V T ,H A T ,r e n a lv e i n
thrombosis, mesenteric thrombosis), pulmonary embo-
lism (PE), myocardial infarction, ischemic stroke, and
peripheral arterial disease, were defined as a pre-trans-
plant thrombosis when the event occurred before liver
transplantation, and were defined as post-transplant
thrombosis when the event occurred after liver transplan-
tation. Thrombotic events were diagnosed by Doppler
ultrasonography, computed tomography scan, or hepatic
biopsies. The follow-up period for donors and recipients
began on the date of liver transplantation, and ended on
the date of death, date of re-transplant, or the end of
study (March 1, 2007). Follow-up periods ranged from 15
d to 8 y (median: 27 months).
Statistical analyses
The Pearson’s chi-square (c2) statistic (or Fisher’se x a c t
test) and the Student’s t test (or Kruskal-Wallis test)
were used to test for differences in the distribution of
dichotomous variables, and for differences in the mean
values of continuous distributions. Forward stepwise
logistic regression was used to identify independent risk
factors for PVT and HAT. The following variables col-
lected at diagnosis were included in the database: gender
(male/female), age (both as a continuous variable, and
grouping patients over and under 16 y of age), the exis-
tence of clinical thrombophilia risk factors, the original
liver disease, and post-transplantation events.
Overall survival (OS) was calculated from the day of
the liver transplantation tod e a t h .K a p l a n - M e i e rl i f e
tables were constructed for survival data and were com-
pared by means of the log-rank test. A census of the
surviving patients was taken on March 1, 2007. The
median follow-up time was 21.7 months (range 1-184.6
months). Results with a P value less than 0.05 were con-
sidered significant.
Results
Thrombophilia in the study population
In recipients, the prevalence of the heterozygote Factor
V Leiden mutation was 7 of 293 (2.4%), the heterozygote
G20210A prothrombin mutation was 13 (4.5%), and the
homozygote C677T MTHFR mutation was 41 (14.1%).
In donors, the prevalence of the heterozygote Factor V
Leiden mutation was 4 out of 222 (1.6%), the heterozy-
gote G20210A prothrombin mutation was 7 (2.8%), and
the homozygote C677T MTHFR mutation was 33 (13%).
Pathology results in this population showed the fol-
lowing: 32 cases (10.9%) had PA < 80%; 34 (11.6%) had
ap r o l o n g e dA P T T( >3 6 ”) and 7 (2.4%) had a reduced
APTT (< 26”); 19 cases (6.5%) had fibrinogen > 400 mg/
dL, and 6 (2%) had fibrinogen < 150 mg/dL; 21 cases
(7.2%) had AT < 80%; 143 (48.8%) had FVIII > 150%,
and one (0.34%) had FVIII < 65%; 30 (10.2%) had PC <
65%; 53 (18.1%) had PS < 65%; 70 (23.9%) had plasma
homocysteine >14 µmol/L. Anti-cardiolipin IgG or IgM
was high in 25 cases (8.5%) (9 IgG, and 17 IgM), and 4
(1.4%) were APC-resistant after OLT (≤ 2).
7 factor V Leiden carrier recipients received a no-Lei-
den liver and all factor V Leiden carrier recipients were
not APC-resistant after transplantation (APCR after
OLT: 2.91, 3.56, 2.36, 3.8, 2.32, 3.17, and 3.23) as
expected. Nevertheless neither of the 2 recipients ana-
lyzed with a factor V Leiden graft were APC-resistant
after the transplant (2.91 and 2.24). Three of four no-
Leiden carrier recipients who were APC-resistant after
OLT showed higher FVIII levels (345%, 219%, 174%),
but only one donor could be tested, and that donor was
found to have a wild-type FV genotype. The Coatest
assay used not include factor V deficient plasma, then
the APC-resistance can be caused by high factor VIII.
Thrombotic events in the study population
Recipients.- Fifty-eight (12.8%) patients developed a
post-transplant thrombotic event (1 ischemic stroke, 6
D V T - P E ,9P V T ,4 1H A T ,a n d1p e r i p h e r a la r t e r i a l
disease).
Living donors.- After surgery, donors’ liver function
recovered well and no bleeding events were recorded.
Donors did not experience thrombotic events, neither
during the immediate post-transplant nor during the
follow-up periods [13].
Thrombotic events after orthotopic liver transplantation
and clinical thrombophilia risk factors
The most frequent post-transplant thrombotic event was
HAT, with a frequency of 9% (41/441 cases, 63.5% of all
post-transplant thrombotic event), and the second most
frequent was PVT (8/441 cases), and one with HAT and
PVT. Of all 50 graft thrombosis cases, 38 were second-
ary liver transplantations. HAT and PVT were most fre-
quent when the recipient was a child (37 of the 58 liver
recipients with post-transplant thrombotic event were
children, versus 42 of 379 without post-transplant
thrombotic event, P < 0.001). The patients with biliary
atresia, all children, showed a higher frequency of post-
transplant thrombotic event (15 cases of 58 with post-
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post-transplant thrombotic event, P < 0.001). The pre-
sence of toxicity was associated with post-transplant
thrombotic event (19 cases of 56 with post-transplant
thrombotic event versus 78 of 368 without post-trans-
plant thrombotic event, p = 0.035) but not the presence
of tumours. (Additional File 1, Table S1).
In the 6 cases with venous thromboembolic processes
(other than PVT or HAT) in the post-transplant period,
the thrombophilic factors were: case 1, complicated
post-surgery period (metabolic diseases, infections, criti-
cal illness neuropathy); case 2, smoking and previous
surgery; case 3, diabetes and tumour associated; cases 4
and 5, relapse HBV or HCV and tumour associated;
case 6, with previous pregnancy complications, she
developed acute lymphoblastic leukemia and a DVT
with slightly low antithrombin. As expected, an
increased frequency of subjects with associated cancer
was found among patients with no-liver related post-
transplant thrombotic event.
Correlation between thrombotic events and the
thrombophilia study
The laboratory findings of the two groups with or with-
out post-transplant thrombotic event are reported in
Table 1. Only higher platelet counts (P < 0.001) and
fibrinogen levels (P < 0.001) were associated with post-
transplant thrombotic event in univariate analysis.
Live donor candidates were excluded from donation if
they presented any abnormalities in the hemostatic
study, due to genetic mutations, anticoagulant protein
deficiencies, factor VIII deficiency or high levels of
anticardiolipin antibodies [13].
Lower recipient platelets count and fibrinogen, AT,
PC, PS were associated with liver disease relapse but not
the FVIII level. (see Additional File 2, Table S2).
Early HAT versus Late HAT
Of the 41 post-transplant HAT, 22 events occurred in
the early post-operatory period, and the remaining 19
took place after at least 3 months post-surgery. Frequent
characteristics of the early HAT group were: pediatric
recipients younger than 2 years old (13 cases), hemody-
namic problems during surgery (4 cases), infections (4
cases), haemolytic anemia (2 cases), previous venoocclu-
sive disease (3 cases), and no-heart-beating donor (2
cases). Frequent characteristics of the late HAT group
were cirrhosis due to HCV reactivation (10 cases), graft
rejection (6 cases), severe infections (3 cases), and hepa-
tocellular tumour (6 cases).
Considering only the population with post-transplant
thrombosis, partial graft resection was associated with
early HAT (13 of 22 early HAT were partial graft
resection versus 2 of 19 late HAT, p = 0.024). Certain
post-transplant events were associated with late HAT,
such as tumor (6 of 19 late HAT were tumor associated
versus 2 of 22 early HAT, p = 0.018), cirrhosis recur-
rence (10 of 19 late HAT were associated with recur-
rence versus 4 of 22 early HAT, p = 0.002), and also
low PC (mean PC was 77% and 90% with and without
recurrence, respectively, p = 0.006). Other events such
as toxicity, showed a tendency to be associated with late
HAT (p = 0.064). Other clinical and laboratory variables
were not especially associated with early or late HAT.
Multivariate study
In the multivariate study the one variable associated
with post-transplant thrombotic event was a high fibri-
nogen level (continuous variable) (HR 1.008; P=0.01),
in the global cohort of liver transplantation (Table 2).
But toxicity as event post-OLT has been associated with
post-transplant thrombotic event in the retrospective
group (Table 3) and high plasma levels of fibrinogen
recipient and low plasma levels of protein C were asso-
ciated post-transplant thrombotic event in the prospec-
tive group (Table 4).
Survival analysis
To determine whether the presence of post-transplant
thrombotic event influenced recipient survival, we per-
formed a survival analysis (Figure 1). The results indi-
cated that only post-transplant thrombotic event was
associated with a poor outcome (median OS was 136.5
and 184.6 months in groups with post-transplant throm-
botic event and without post-transplant thrombotic
event, respectively, P < 0.03). Figure 2 shows the influ-
ence of level FVIII on the overall survival separately in
both young and elderly groups. Liver disease relapse
(no/yes) (HR 6.609; 95%CI, 2.674-16.335), high levels of
FVIII (continuous variable) (HR 1.0008; 95%CI, 1.001-
1.015) and low levels of antithrombin (continuous vari-
able) (HR 0.946; 95%CI, 0.921-0.971) have been inde-
pendently associated with mortality from the time of
liver transplantation in a multivariable Cox regression
model (Table 5).
Discussion
Post-transplant HAT and/or PVT increase the potential
for graft loss. The frequency of post-transplant HAT has
been previously recorded as 4.5% to 6%[14,15]. In our
study, the most frequent post-transplant thrombotic
event was HAT, with a frequency of 9% (41/441 cases,
63.5% of all post-transplant thrombotic event). However,
there is no extensive thrombophilia study in a large
cohort of liver recipients. We evaluated the thrombophi-
lia-associated risk factors and their clinical impact was
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Page 4 of 9Table 1 Hypercoagulability study in association with post-transplant thromboses
With thrombosis post-
transplant (26 Cases)
Without thrombosis post-
transplant (267 Cases)
Significance
RECIPIENT STUDY
Platelets (×10
9/L) 327.27 ± 88.0 264.89 ± 73.7 p < 0.001
PA (%) 101.96 ± 21.5 101.79 ± 16.4 p = 0.962
APTT (seconds) 31.24 ± 6.1 31.08 ± 4.4 p = 0.866
TT (seconds) 13.8 ± 2.2 14.22 ± 1.9 p = 0.301
Fibrinogen (mg/dL) 327.3 ± 88.7 264.89 ± 73.7 p < 0.001
AT (U/dL) 107.57 ± 18.3 99.57 ± 15.3 p = 0.013
PC chromogenic (U/dL) 61.34 ± 41.9 74.69 ± 39.8 p = 0.069
PC anticoagulant (U/dL) 94.68 ± 18.99 102.61 ± 27.5 p = 0.065
PS free antigen (U/dL) 84.0 ± 12.7 77.85 ± 14.2 p = 0.038
PS functional (U/dL) 95.4 ± 24.9 83.44 ± 22.3 p = 0.011
PS total (U/dL) 90.0 ± 9.0 93.9 ± 18.3 p = 0.716
Factor VIII (UI/dL 168.77 ± 60.8 153.95 ± 56.9 p = 0.209
ACA IgG (uFl) 5.84 ± 5.0 7.56 ± 16.49 p = 0.605
ACA IgM (uFl) 11.24 ± 18.64 9.3 ± 14.68 p = 0.539
Plasma homocysteine (μmoles/L) 13.79 ± 3.35 14.31 ± 8.7 p = 0.585
Factor V Leiden mutation (N°) (heterozygous) in
recipient
1/26 6/264 p = 0.618
Prothrombin 20210A mutation (N°) (heterozygous) in
recipient
0/26 13/264 p = 0.247
C677T MTHFR mutation (N°) (wild type/heterozygous/
homozygous) in recipient
13/8/4 102/117/37 p = 0.402
APCR 2.86 ± 0.51 2.92 ± 0.51 p = 0.582
DONOR STUDY
Factor V Leiden mutation (N°) (heterozygous) in donor 0/26 4/196 p = 0.454
Prothrombin 20210A mutation (N°) (heterozygous) in
donor
1/26 6/194 p = 0.865
C677T MTHFR mutation (N°) (wild type/heterozygous/
homozygous) in donor
9/14/3 63/101/28 p = 0.915
PA (pro-thrombin activity); APTT (activated partial thromboplastin time); TT (thrombin clotting time); AT (anti-thrombin); PC (protein C); PS (protein S); ACA
(anticardiolipin antibody); APCR (activated protein C resistance); (MTHFR) 5,10-methylenetetrahydrofolate reductase.
Table 2 Logistic Regression analysis of factors associated with post-transplant thrombosis IN GLOBAL COHORT OF
LIVER TRANSPLANTATION.
Variable p Hazard Ratio (CI)
CHILD/ADULT RECIPIENT 0.138
TOXICITY AS EVENT POSTRANSPLANT (YES/NO) 0.106
ASSOCIATED TUMOR 0.952
CAUSE OF LIVER TRANSPLANTATION 0.443
FIBRINOGEN RECIPIENT (CONTINUOUS VARIABLE) < 0.001 1.010 (1.004-1.016)
PLATELET COUNT RECIPIENT (CONTINUOUS VARIABLE) 0.443
FVIII LEVEL RECIPIENT (CONTINUOUS VARIABLE) 0.629
ATIII RECIPIENT (CONTINUOUS VARIABLE) 0.237
FREE PROTEIN S RECIPIENT 0.473
PROTEIN C RECIPIENT 0.052
The one variable associated with post-transplant TE was a high fibrinogen level (continuous variable) (HR 1.008; P=0.01), in the global cohort of liver
transplantation.
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neity of the study population are limitations of our
study.
Liver transplantation itself also changes the dynamics
of coagulation, with a pro-coagulant pattern in the first
weeks post-transplant. Due to the thrombophilia study
was carried out between 1.2 months to 4.1 months
post-transplant, thrombophilic abnormalities in immedi-
ate post-surgery, with influence in the development of
early HAT, could be underestimated. Nevertheless, we
detected thrombophilic abnormalities that were still
evident during the first 3 months post-surgery or during
the late post-transplant period, and which were asso-
ciated with HAT.
The importance of genetic thrombophilia risk factors
in PVT has been investigated in several studies [16-19]
but all of them have excluded cases with local risk fac-
tors. The incidence of Factor V Leiden, prothrombin
mutation, decreased PC, decreased PS, and decreased
AT has been recorded between 3-30%, 3-22%, 0-26%, 2-
43%, and 1-26%, respectively. In our study the incidence
of decreased PC, decreased PS, and decreased AT was
2.4%, 4.5%, 10.2%, 18%, and 7.2%, respectively. The inci-
dences of decreased PC, PS and AT were higher than
that observed in the general population. Nevertheless,
these deficiencies coincided with deteriorating liver
function in most cases.
Most of the coagulation changes due to genetic muta-
tions in the recipient are corrected by liver transplanta-
tion. Of the 293 patients screened for genetic analysis of
Factor V Leiden and who underwent functional studies
of APCR after OLT, 7 heterozygous carriers of Factor V
Leiden displayed a loss of APCR after transplantation, as
previously described [20-22]. In our study, recipients of
graft Factor V Leiden did not acquire APCR, probably
because the platelet derived Factor V originates from
the plasma pool [23-25]. However, these results do not
correlate with previous work which states that APCR
associated with a Factor V Leiden donor is fully trans-
ferable to the graft recipient [22].
Some of the variables associated with post-transplant
thrombotic event could relate to difficulties in surgical
technique, such as in a child recipient, and also their
primary cause of liver transplantation, biliary atresia. In
a recent study [26], post-transplant complication rates,
including the re-operation rate, were higher in the
younger group. In our study, fibrinogen level was the
one variable independently associated with post-trans-
plant thrombotic event in the global cohort of liver reci-
pients. Previously this factor has been associated both
with thrombosis and inflammation. A meta-analysis
showed that risk of coronary heart disease may increase
1.8 fold for 1 g/L of increased fibrinogen, independent
of traditional risk factors [27]. But, in the retrospective
cohort of recipients, the toxicity was the only variable
independently associated. This factor could be involved
in graft thrombosis due to its role in endothelial injury
and inflammation. Plasma levels of fibrinogen (high) and
protein C recipient (low) were associated post-transplant
thrombotic event in the prospective group. Low plasma
levels of protein C recipient was associated, in this
work, with liver disease relapse (Additional File 2, Table
S2), and this fact could be a consequence of disbalance
of coagulation factors in terminal cirrhosis [28]. A pre-
vious paper had shown that PC was decreased at day 7
Table 3 Logistic Regression analysis of factors associated
with post-transplant thrombosis IN RETROSPECTIVE
COHORT OF LIVER TRANSPLANTATION.
Variable p Hazard Ratio
(CI)
CHILD/ADULT RECIPIENT 0.213
TOXICITY AS EVENT POSTRANSPLANT (YES/
NO)
0.019 4.484 (1.284-
15.664)
ASSOCIATED TUMOR 0.544
CAUSE OF LIVER TRANSPLANTATION 0.985
FIBRINOGEN RECIPIENT (CONTINUOUS
VARIABLE)
0.115
PLATELET COUNT RECIPIENT (CONTINUOUS
VARIABLE)
0.416
FVIII LEVEL RECIPIENT (CONTINUOUS
VARIABLE)
0.646
ATIII RECIPIENT (CONTINUOUS VARIABLE) 0.087
FREE PROTEIN S RECIPIENT 0.635
PROTEIN C RECIPIENT 0.261
Only toxicity as event post-OLT has been associated with post-transplant TE in
the retrospective group
Table 4 Logistic Regression analysis of factors associated
with post-transplant thrombosis IN PROSPECTIVE
COHORT OF LIVER TRANSPLANTATION.
Variable p Hazard Ratio
(CI)
CHILD/ADULT RECIPIENT 0.075 0.056 (0.002-
279)
TOXICITY AS EVENT POSTRANSPLANT (YES/
NO)
0.096
ASSOCIATED TUMOR 0.053
CAUSE OF LIVER TRANSPLANTATION 0.253
FIBRINOGEN RECIPIENT (CONTINUOUS
VARIABLE)
0.023 1.023 (1.003-
1.044)
PLATELET COUNT RECIPIENT (CONTINUOUS
VARIABLE)
0.743
FVIII LEVEL RECIPIENT (CONTINUOUS
VARIABLE)
0.918
ATIII RECIPIENT (CONTINUOUS VARIABLE) 0.063
FREE PROTEIN S RECIPIENT 0.941
PROTEIN C RECIPIENT 0.025 0.950 (0.909-
0.994)
High plasma levels of fibrinogen recipient and low plasma levels of protein C
were associated post-transplant TE in the prospective group.
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LRT groups with complications, respectively [29].
Nevertheless, high plasma fibrinogen levels are not a
consequence of liver function alteration, and could be
an important pro-thrombotic factor in development
graft thrombosis that has not been previously described.
Our results were in agreement with previous studies
[12] showing that the presence of post-transplant
thrombotic event, HAT in the majority of cases, in this
liver recipient cohort influenced recipient overall survi-
val. High factor VIII was associated with a poor out-
come, as previously reported. Levels of factor VIII, a
potent pro-coagulant involved in thrombin generation,
increased progressively with Child-Pugh Score (from
Child-Pugh class A to C)[30]. A correlation between the
severity of liver disease and von Willebrand factor
(VWF) plasma antigen levels has been previously docu-
mented [31,32]. In agreement with other authors [33],
Figure 1 Liver transplant recipient overall survival (OS). A. Post-transplant thrombosis was associated with a poor outcome (P < 0.03). B.
High FVIII:C levels were associated with a poor outcome: the median OS was 69.6 and 132.1 months in groups with high and low FVIII:C,
respectively (P < 0.003). Median follow-up was 21.7 months (range 1-184.6 months).
Figure 2 High FVIII:C levels and Recipient Overall Survival. High FVIII:C levels were associated with a poor outcome separately in both
young and elderly groups (Log Rank 8.56; p = 0.0034).
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Page 7 of 9we emphasize the need for studies to evaluate the clini-
cal relevance of including thrombotic risk factors (such
as factor VIII associated to poor outcome) in the Prog-
nostic scores ej. Model for End-stage Liver Disease
(MELD).
Conclusion
To the best of our knowledge, this is the first extensive
thrombophilia study in a large cohort of liver recipients.
Therefore, our study does not support universal long
thrombophilia screening in liver recipients. High fibrino-
gen and decreased protein C are associated with allo-
graft thrombosis. The practical impact these findings
could be the need to include parameters such as fibrino-
gen and protein C levels as risk factors of graft throm-
bosis and to assess the effect of anticoagulation
prophylaxis in this group of risk. Further studies are
required in order to assess the clinical relevance of these
parameters in prospective studies.
Additional material
Additional file 1: Table S1. Clinical thrombophilic risk factors in
association with post-transplant thromboses.
Additional file 2: Table S2. Mean Comparison (T Student Test) of
study variables in function of recidive as event post-transplant.
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